Here are five points:
1. The firm has a $65 price objective on NuVasive’s stock, up from their previous price objective of $60.
2. NuVasive currently has an average rating of buy and an average target price of $58.63.
3. NuVasive has a 12-month low of $41.52 and a 12-month high of $56.61.
4. T he stock’s 50 day moving average price is $50.44 and its 200-day moving average price is $50.81.
5. The stock has a market capitalization of $2.51 billion.
More articles on devices:
Grab some rays — Active individuals may need to maintain higher vitamin D levels to minimize stress fracture risk
Houston Methodis Hospital implements CT-free robotic surgery — 5 key points
OrthoSensor raises $3.9M in funding: 5 key notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
